{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:51:13Z","timestamp":1787611873653,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Orthop Relat Res"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bisphosphonates reduce the risk of fractures associated with osteoporosis but increase the risk of atypical subtrochanteric femur fractures. After unilateral atypical femur fracture, there is risk of contralateral fracture, but the indications for prophylactic fixation are controversial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Questions\/purposes<\/jats:title>\n            <jats:p>The purpose of this study is to use Markov modeling to determine whether contralateral prophylactic femur fracture fixation is cost-effective after a bisphosphonate-associated atypical femur fracture and, if so, what patient-related factors may influence that determination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Markov modeling was used to determine the cost-effectiveness of contralateral prophylactic fixation after an initial atypical femur fracture. Simulated patients aged 60 to 90 years were included and separated into standard and high fracture risk cohorts. Patients with standard fracture risk were defined as those presenting with one atypical femur fracture but without symptoms or findings in the contralateral femur, whereas patients with high fracture risk were typified as those with more than one risk factor, including Asian ethnicity, prodromal pain, femoral geometry changes, or radiographic findings in the contralateral femur. Outcome probabilities and utilities were derived from studies matching to patient characteristics, and fragility fracture literature was used when atypical femur fracture data were not available. Associated costs were largely derived from Medicare 2015 reimbursement rates. Sensitivity analysis was performed on all model parameters within defined ranges.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Prophylactic fixation for a 70-year-old patient with standard risk for fracture costs USD 131,300\/quality-adjusted life-year (QALY) and for high-risk patients costs USD 22,400\/QALY. Sensitivity analysis revealed that prophylaxis for high-risk patients is cost-effective at USD 100,000\/QALY when the cost of prophylaxis was less than USD 29,400, the probability of prophylaxis complications was less than 21%, or if the patient was younger than 89 years old. The parameters to which the model was most sensitive were the cost of prophylaxis, patient age, and probability of prophylaxis-related complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Prophylactic fixation of the contralateral side after unilateral atypical femur fracture is not cost-effective for standard-risk patients but is cost-effective among high-risk patients between 60 and 89 years of age with a high risk for an atypical femur fracture defined by patients with more than one risk factor such as Asian ethnicity, prodromal pain, varus proximal femur geometry, femoral bowing, or radiographic changes such as periosteal beaking and a transverse radiolucent line. However, our findings are based on several key assumptions for modeling such as the probability of fractures and complications, the costs associated for each health state, and the risks of surgical treatment. Future research should prospectively evaluate the degree of risk contributed by known radiographic and demographic parameters to guide management of the contralateral femur after a patient presents with an atypical femur fracture.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Level of Evidence<\/jats:title>\n            <jats:p>Level III, economic and decision analyses.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/corr.0000000000000545","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T06:26:56Z","timestamp":1541226416000},"page":"480-490","source":"Crossref","is-referenced-by-count":20,"title":["Prophylactic Fixation Can Be Cost-effective in Preventing a Contralateral Bisphosphonate-associated Femur Fracture"],"prefix":"10.1097","volume":"477","author":[{"given":"Sam Y.","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie Y.","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Longoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Shachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius A.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,10,26]]},"reference":[{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1007\/s11999-011-1828-8","article-title":"Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures","volume":"469","author":"Banffy","year":"2011","journal-title":"Clin Orthop Relat Res"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00198-010-1411-2","article-title":"Oral bisphosphonates are associated with reduced mortality after hip fracture","volume":"22","author":"Beaupre","year":"2011","journal-title":"Osteoporos Int"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00003086-200006000-00005","article-title":"Percutaneous treatment of peritrochanteric fractures using the Gamma nail","volume":"375","author":"Bellabarba","year":"2000","journal-title":"Clin Orthop Relat Res"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N Engl J Med"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11999-013-3034-3","article-title":"Bundled payments in total joint arthroplasty: targeting opportunities for quality improvement and cost reduction","volume":"472","author":"Bozic","year":"2014","journal-title":"Clin Orthop Relat Res"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/BOT.0b013e31827240ae","article-title":"Surgical treatment improves clinical and functional outcomes for patients who sustain incomplete bisphosphonate-related femur fractures","volume":"27","author":"Egol","year":"2013","journal-title":"J Orthop Trauma"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1007\/s11999-013-2963-1","article-title":"Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails","volume":"472","author":"Egol","year":"2014","journal-title":"Clin Orthop Relat Res"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.injury.2008.09.010","article-title":"Quality of life after a subtrochanteric fracture: a prospective cohort study on 87 elderly patients","volume":"40","author":"Ekstrom","year":"2009","journal-title":"Injury"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/BOT.0b013e3181b01dce","article-title":"Is prophylactic fixation a cost-effective method to prevent a future contralateral fragility hip fracture?","volume":"24","author":"Faucett","year":"2010","journal-title":"J Orthop Trauma"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","article-title":"Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case\/case series studies","volume":"47","author":"Giusti","year":"2010","journal-title":"Bone"},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2106\/JBJS.N.00075","article-title":"Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry","volume":"96","author":"Hagen","year":"2014","journal-title":"J Bone Joint Surg Am"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/00005650-200011000-00006","article-title":"Patterns of rehabilitation utilization after hip fracture in acute hospitals and skilled nursing facilities","volume":"38","author":"Harada","year":"2000","journal-title":"Med Care"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.2106\/00004623-200412000-00011","article-title":"Prophylactic pinning of the contralateral hip after unilateral slipped capital femoral epiphysis","volume":"86","author":"Kocher","year":"2004","journal-title":"J Bone Joint Surg Am"},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","article-title":"An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?","volume":"39","author":"Kwek","year":"2008","journal-title":"Injury"},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bone.2012.02.632","article-title":"Clinical correlates of atypical femoral fracture","volume":"51","author":"Lo","year":"2012","journal-title":"Bone"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/BOT.0000000000000851","article-title":"Intramedullary nail fixation of atypical femur fractures with bone marrow aspirate concentrate leads to faster union: a case-control study","volume":"31","author":"Lovy","year":"2017","journal-title":"J Orthop Trauma"},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ocl.2014.03.006","article-title":"Use of bisphosphonates in orthopedic surgery: pearls and pitfalls","volume":"45","author":"Lozano-Calderon","year":"2014","journal-title":"Orthop Clin North Am"},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier","year":"2012","journal-title":"Arch Intern Med"},{"key":"R25-20230814","first-page":"632","article-title":"Subtrochanteric stress fractures in patients on oral bisphosphonate therapy: an emerging problem","volume":"77","author":"Murphy","year":"2011","journal-title":"Acta Orthop Belg"},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the USD 50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use","volume":"22","author":"Neviaser","year":"2008","journal-title":"J Orthop Trauma"},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11914-010-0007-2","article-title":"Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates","volume":"8","author":"Nieves","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"450148","DOI":"10.1155\/2013\/450148","article-title":"Prophylactic nailing of incomplete atypical femoral fractures","volume":"2013","author":"Oh","year":"2013","journal-title":"ScientificWorldJournal"},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jama.2011.190","article-title":"Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women","volume":"305","author":"Park-Wyllie","year":"2011","journal-title":"JAMA"},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1302\/0301-620X.74B2.1544965","article-title":"Cost-benefit analysis of hip fracture treatment","volume":"74","author":"Parker","year":"1992","journal-title":"J Bone Joint Surg Br"},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0020-1383(02)00282-6","article-title":"Outcome following a second hip fracture","volume":"34","author":"Pearse","year":"2003","journal-title":"Injury"},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/BOT.0b013e3182a22744","article-title":"A risk calculator for short-term morbidity and mortality after hip fracture surgery","volume":"28","author":"Pugely","year":"2014","journal-title":"J Orthop Trauma"},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/bmj.38643.663843.55","article-title":"Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study","volume":"331","author":"Roche","year":"2005","journal-title":"BMJ"},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00774-012-0358-0","article-title":"Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series","volume":"30","author":"Sasaki","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N Engl J Med"},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2106\/JBJS.M.00603","article-title":"Cost-effectiveness analysis of fixation options for intertrochanteric hip fractures","volume":"96","author":"Swart","year":"2014","journal-title":"J Bone Joint Surg Am"},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12891-016-1086-8","article-title":"Management of atypical femoral fracture: a scoping review and comprehensive algorithm","volume":"17","author":"Toro","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s001980170015","article-title":"Impact of hip and vertebral fractures on quality-adjusted life years","volume":"12","author":"Tosteson","year":"2001","journal-title":"Osteoporos Int"},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","article-title":"Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012","volume":"57","author":"Wysowski","year":"2013","journal-title":"Bone"},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1469-0691.2010.03331.x","article-title":"Understanding cost-effectiveness","volume":"16","author":"Zilberberg","year":"2010","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Orthopaedics &amp; Related Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003086-201903000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T05:00:23Z","timestamp":1691989223000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003086-201903000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,26]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/corr.0000000000000545","relation":{},"ISSN":["0009-921X"],"issn-type":[{"value":"0009-921X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,26]]}}}